GleamWall
中文EN

CVKD Cadrenal Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1937993 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY29.8%
TTM EPS YoY57.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-358.3%
ROA-267.9%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets16.0%
Debt / equity0.00x
Current ratio6.26x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.96x
Accruals ratio-10.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$224,576$705,151$771,508$666,323$688,465$1.08M$1.67M$1.54M
SG&A expense$1.04M$2.63M$1.74M$2.40M$2.04M$2.66M$2.25M$2.74M
Operating income-$1.27M-$3.34M-$2.51M-$3.07M-$2.73M-$3.73M-$3.93M-$4.28M
Net income-$1.25M-$3.32M-$2.50M-$3.04M-$2.69M-$3.67M-$3.85M-$4.19M
EBITDA-$1.26M-$3.34M-$2.51M-$3.06M-$2.73M-$3.73M-$3.92M-$4.28M
EPS (basic)-0.31-1.14-1.04—-1.31-1.87-2.09—
EPS (diluted)-0.31-1.14-1.04—-1.31-1.87-2.09—
Dividends declared per share———0.000.000.0016.50—
Weighted avg. shares (diluted)4.06M2.91M2.41M—2.04M1.96M1.84M—
Balance sheet
Cash & equivalents$3.06M$2.39M$2.31M$4.01M$3.86M$5.57M$7.34M$10.02M
Current assets$3.45M$5.58M$2.86M$4.32M$4.08M$5.97M$7.94M$10.11M
PP&E, net$2,274$2,675$4,619$5,174$5,729$4,277$4,678$6,944
Total assets$3.46M$5.59M$2.86M$4.33M$4.09M$5.98M$7.95M$10.12M
Current liabilities$551,336$1.50M$1.06M$1.59M$1.35M$1.68M$1.84M$2.68M
Total liabilities$551,336$1.50M$1.06M$1.59M$1.35M$1.68M$1.84M$2.68M
Shareholders' equity$2.90M$4.09M$1.80M$2.74M$2.73M$4.30M$6.11M$7.44M
Shares outstanding4.06M3.10M2.51M2.34M2.06M2.01M1.91M1.78M
Cash flow statement
Operating cash flow-$1.92M-$2.23M-$3.00M-$2.57M-$2.36M-$3.03M-$4.65M-$1.79M
Capital expenditure———$0$1,853$0$3,251—
Free cash flow———-$2.57M-$2.36M-$3.03M-$4.65M—
Investing cash flow———$0-$1,853$0-$3,251—
Financing cash flow$2.58M$2.31M$1.30M$2.72M$648,355$1.26M$1.97M$7.45M
Depreciation & amortization$400$504$555$555$401$401$5,517$407
Stock-based compensation$108,427$672,102$252,364$325,103$473,384$592,644$548,765$763,208

Free plan shows the latest 8 periods; Pro shows all 18 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.